Advanced Filters
noise

neoplasms Clinical Trials

A listing of neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,180 clinical trials
O Osama Soliman, MBBCH, PHD

Understanding CARdiac Events in Breast Cancer

In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. This research is focused …

18 - 90 years of age Female Phase N/A
S Shuhui Song

A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method

The study is a real-world observational clinical study. Patients diagnosed as gastric cancer through histopathology were screened and enrolled. Before anti-tumor treatment, gastroscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. The investigators will perform a drug sensitivity testing based on a novel …

18 - 80 years of age All Phase N/A
S Sherry R Azmy, Demonstrator of pathology

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

years of age All Phase N/A

Transcriptional Map of Ovarian Cancer at the Single Cell Level

In 2020, epithelial ovarian cancer (EOC) accounts for 313,959 new cases and 207,252 deaths worldwide. The standardized 5-year net survival of a woman with EOC is 44% for cases diagnosed between 2005-2010. This is because 2 out of 3 cancers are found at an advanced stage with invasion beyond the …

18 - 80 years of age Female Phase N/A
H Hongyu Xie, PhD

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels …

18 - 75 years of age Female Phase N/A
P Peng Peng

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

20 - 70 years of age Female Phase N/A
S Sharareh Sazesh, MS

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

18 years of age Female Phase N/A
r rutie YIN, M.D.

Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients

Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an elevated CA125 indicates a later stage and a worse prognosis. However about 20% of patients with …

years of age Female Phase N/A
J Jung-Yun Lee

Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors

Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status are unknown. Previous study, we analyzed the dynamic immunological changes in peripheral T cells during PARP inhibitor maintenance therapy and found predictive biomarkers. The purpose …

19 - 85 years of age Female Phase N/A
C Christine Pappaterra

Clinical Pre-screening Protocol for Ovarian Cancer

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. …

18 years of age Female Phase N/A

Simplify language using AI